CASE REPORT OF INFLIXIMAB LEADING TO DISEASE CONTROL IN A MAN WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAD PREVIOUSLY FAILED ETANERCEPT

被引：0

作者：

Shenker, N. ^{[1
]}

Haigh, R. ^{[2
]}

Michell, L. ^{[1
]}

Calin, A. ^{[1
]}

机构：

[1] Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England

[2] Royal Devon & Exeter NHS Trust, Dept Rheumatol, Exeter, Devon, England

来源：

RHEUMATOLOGY | 2003年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：91 / 91

页数：1

共 29 条

[21] Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
Stevenson, Matt
Archer, Rachel
Tosh, Jon
Simpson, Emma
Everson-Hock, Emma
Stevens, John
Hernandez-Alava, Monica
Paisley, Suzy
Dickinson, Kath
Scott, David
Young, Adam
Wailoo, Allan
HEALTH TECHNOLOGY ASSESSMENT, 2016, 20 (35) : 1 - +
[22] A German follow-up long-term observation over 2 years in patients who had previously completed a clinical study to evaluate the effectiveness and safety of the TNF-alpha antibody infliximab in the treatment of patients with rheumatoid arthritis
Kalden, JR
Soerensen, H
Haentzschel, H
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 271 - 271
[23] Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for the Treatment of Rheumatoid Arthritis Not Previously Treated with Disease-Modifying Antirheumatic Drugs and Aft er the Failure of Conventional Disease-Modifying Antirheumatic Drugs Only: Systematic Review and Economic Evaluation
Lunzer, R.
JOURNAL FUR MINERALSTOFFWECHSEL & MUSKULOSKELETTALE ERKRANKUNGEN, 2016, 23 (02): : 61 - 61
[24] TOFACITINIB VERSUS BIOLOGIC TREATMENTS WITH AND WITHOUT METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO TRADITIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS - A NETWORK META-ANALYSIS
Vieira, M. G.
Wallenstein, G. V.
Bradley, J. D.
Gruben, D.
Koncz, T.
Zwillich, S. H.
Jansen, J. P.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 375 - 375
[25] Validity of a self-report questionnaire about osteoporosis used in a case control study of subjects with scleroderma, rheumatoid arthritis, and non-inflammatory musculoskeletal disease
Hans, GK
Pope, J
JOURNAL OF RHEUMATOLOGY, 2004, 31 (07) : 1446 - 1446
[26] Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome
Chellapandian, Deepak
Milojevic, Diana
FRONTIERS IN PEDIATRICS, 2023, 11
[27] Addition of leflunomid therapy to the active rheumatuid arthritis patients, who had been treated with three-disease modifying anti-rheumatic drug (DMARD) combination therapy: A preliminary report of the short term adverse effects
Caiguneri, M
Apras, S
Ozbalkan, Z
Ertenli, I
Kiraz, S
Ozturk, MA
Akdogan, A
Ureten, K
Onat, A
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 408 - 409
[28] PATHOLOGIC ASPECTS OF ACUTE EPIDEMIC HEPATITIS, WITH ESPECIAL REFERENCE TO EARLY STAGES - REPORT OF A SERIES OF 10 CASES, INCLUDING A CASE IN WHICH THERE WAS SPONTANEOUS RUPTURE OF THE SPLEEN AND 6 CASES OF FULMINATING DISEASE IN PATIENTS WHO HAD BEEN WOUNDED SEVERAL MONTHS PREVIOUSLY
WOOD, DA
ARCHIVES OF PATHOLOGY, 1946, 41 (04): : 345 - +
[29] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH OLOKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE, MODERATE TO SEVERE RHEUMATOID ARTHRITIS WHO HAD FAILED PREVIOUS ANTI-TNF THERAPY: RESULTS FROM THE RA0056 DOUBLE-BLIND, RANDOMIZED CONTROLLED STUDY, AND RA0057, ITS OPEN-LABEL EXTENSION
Genovese, M.
Fleischmann, R.
Furst, D.
Janssen, N.
Carter, J.
Dasgupta, B.
Pitzalis, C.
Vasyutin, I.
Kaviarasu, T.
Krotkova, A.
Durez, P.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 718 - 719

← 1 2 3 →